Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alaunos Therapeutics (TCRT) Common Equity (2016 - 2025)

Alaunos Therapeutics (TCRT) has disclosed Common Equity for 15 consecutive years, with $2.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 2.79% year-over-year to $2.8 million, compared with a TTM value of $2.8 million through Sep 2025, up 2.79%, and an annual FY2024 reading of $2.1 million, down 67.29% over the prior year.
  • Common Equity was $2.8 million for Q3 2025 at Alaunos Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $105.6 million in Q1 2021 and bottomed at $1.1 million in Q1 2025.
  • Average Common Equity over 5 years is $30.2 million, with a median of $21.6 million recorded in 2023.
  • The sharpest move saw Common Equity crashed 83.74% in 2024, then increased 2.79% in 2025.
  • Year by year, Common Equity stood at $58.1 million in 2021, then crashed by 33.59% to $38.6 million in 2022, then crashed by 83.64% to $6.3 million in 2023, then plummeted by 67.29% to $2.1 million in 2024, then skyrocketed by 35.72% to $2.8 million in 2025.
  • Business Quant data shows Common Equity for TCRT at $2.8 million in Q3 2025, $3.7 million in Q2 2025, and $1.1 million in Q1 2025.